Spinnaker Life Sciences Strategy Consulting

When considering strategic opportunities – whether partnerships, licensing agreements, or acquisitions – companies often face a complex landscape of interrelated factors. Successfully navigating these initiatives requires a deep understanding of the asset’s value, both internally and externally, and thorough diligence to identify the optimal path forward and maximize ROI.   Our expertise includes evaluating markets, indications, and treatments through primary and secondary research, robust analytics, accurate revenue forecasting and development of multi-scenario valuation models. These capabilities empower clients with the insights needed to craft optimal partnerships and strategies that drive long term value and success.   Curious about how our insights can ensure you are able to maximize partnership value and strategic growth opportunities? Visit our website at the link below. https://lnkd.in/eQff-Gfx   #Biotech #StrategicAlliances #PartnershipStrategy Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Welcome to the December edition of the Spinnaker Insights newsletter. This month, we explore how a variety of factors are driving a transformation in med device commercialization strategies. #LifeScienes #Commercialization #MedicalDevice

In the ever-changing world of pharma and biotech, uncertainty is the only certainty. Financial Planning & Analysis (FP&A) teams are increasingly turning to scenario planning to navigate risks and boost resilience. By modeling a range of potential outcomes, companies can better manage pipeline risks, regulatory complexities, market shifts, and macro-level challenges like economic instability. Scenario planning enables more strategic flexibility, optimizes resource allocation, and strengthens investor confidence. It’s not just about forecasting; it’s about preparing for multiple contingencies and turning uncertainty into a competitive advantage. Click the link below to learn more. https://lnkd.in/eVY9tUCX #Pharma #Biotech #FinancialPlanning #ScenarioPlanning #Strategy #FPA Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Advancing early-stage drug candidates into the clinic involves a series of pivotal decisions. Yet the downstream commercial implications must remain a critical consideration. At Spinnaker, we specialize in assessing current and future market opportunities, delivering actionable insights to ensure early development decisions align with long-term commercial success. Our expertise helps companies leverage early-stage commercial insights to shape strategic plans that drive value and mitigate risk. Want to learn more about how we can support your journey from the clinic to the market? Visit our website at the link below. https://lnkd.in/d7EHEDMY #Biotech #Pharma #ProductStrategy #CommericalStrategy #LifeSciences Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Executive leadership teams juggle countless initiatives, often leading to misalignment between financial goals and strategic priorities. At Spinnaker, we specialize in bridging this gap. From crafting operating budgets that align with corporate strategies to refining development scenarios, we help organizations realign, innovate, and seize growth opportunities. Our approach includes fostering consistent, transparent discussions among executive teams and ensuring clarity with the Board of Directors – essential for sustained success. We specialize in navigating through challenging waters. Ready to explore how we can support your journey? Visit our website at the link below. https://lnkd.in/eR-YXrzS #Biotech #CorporateStrategy #FPA Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Last week's Com-X gathering in San Diego, sponsored by Spinnaker, was attended by two of our Managing Partners, Harris Kaplan and Dane C.. The event proved to be a great success, featuring insightful discussions with some of San Diego’s foremost life sciences executives, as well as an engaging presentation by Bill Rastetter. Thank you to Com-X Network San Diego for the opportunity to participate in this outstanding event!   #Biotech #LifeSciences #ComX #BioPharma #Networking

Over the last 15 years, about half of all new product launches have fallen short of their pre-launch forecasts. In today’s high-stakes healthcare market, achieving new product success requires more than clinical innovation and a better product—it’s about recognizing and mastering the human side of change. Success depends on understanding what it takes to shift people’s behavior away from the status quo. Spinnaker’s RAMPx model, adapted specifically for the life sciences from Everett Rogers' Diffusion of Innovation framework, provides a data-driven approach to realistically assess and enhance a new product’s future commercialization potential. By aligning product design to overcome people’s adoption barriers—such as ease of adoption and perceived risk—companies can accelerate uptake by clearly demonstrating a new product’s value in a crowded and cautious market. Citeline Commercial In Vivo has made both Part 1 and Part 2 of this series available outside its paywall. We invite you to explore these insights and connect with Harris Kaplan to discuss how to achieve meaningful impact in today’s value-driven healthcare environment—and how the RAMPx model can help your company succeed. Click the link below for Part 2. https://lnkd.in/eabpFkNX #NewProduct #Commercialization #LaunchRorecast #Healthcare #Biotech Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Yesterday morning, we were excited to celebrate Cellbricks Therapeutics opening their first US office in "the most innovative square mile on the planet" with a ribbon-cutting ceremony led by the Mayor of Berlin, Kai Wegner. Their work in 3D bioprinting is redefining the possibilities of next-gen tissue engineering, and the opening of their Kendall office marks a major milestone in their global expansion. We're thrilled to support their continued growth and success.   #BioPrinting #3DPrinting #HealthcareInnovation #Cellbricks #CambridgeMA #Biotech #LifeSciences #TissueEngineering #RegenerativeMedicine

The Inflation Reduction Act (IRA) of 2022, the rise of value-based care models, and increasing global reliance on Health Technology Assessments (HTAs) have heightened scrutiny on pharmaceutical pricing. In this new environment, Health Economics and Outcomes Research (HEOR) is cementing itself as an valuable framework for justifying costs. With advancements in decentralized trials (DCTs) and AI, HEOR’s role is likely to expand, enabling more efficient data collection and predictive analysis of real-world patient outcomes. Click the link below to learn more. https://lnkd.in/ebGjhgQm #HEOR #HealthEconomicsAndOutcomesResearch #InflationReductionAct #HealthTechnologyAssessments Subscribe here to receive our latest insights and newsletters: https://lnkd.in/eGAaapyA

Welcome to the November edition of the Spinnaker Insights newsletter. This month, Managing Partner Harris Kaplan provides insight into why new products struggle to achieve success in today's healthcare system. #LifeSciences #Healthcare #Commercialization